{"id":"prevenar-wyeth","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site erythema"},{"rate":"15-30","effect":"Injection site swelling"},{"rate":"10-25","effect":"Fever"},{"rate":"15-25","effect":"Irritability"},{"rate":"10-20","effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prevenar contains polysaccharide antigens from multiple serotypes of S. pneumoniae conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent immune responses. The vaccine primes both humoral and cellular immunity to prevent invasive pneumococcal disease and pneumococcal pneumonia caused by the included serotypes.","oneSentence":"Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:12.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children"},{"name":"Prevention of pneumococcal pneumonia in adults"}]},"trialDetails":[{"nctId":"NCT00611663","phase":"PHASE2, PHASE3","title":"Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-05","conditions":"Lupus Erythematosus, Systemic","enrollment":47},{"nctId":"NCT00907777","phase":"PHASE3","title":"Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-23","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":52},{"nctId":"NCT02494999","phase":"PHASE3","title":"A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-06","conditions":"Pneumonia","enrollment":1200},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT02308540","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2015-01-12","conditions":"Pneumococcal Disease","enrollment":346},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00911144","phase":"PHASE3","title":"Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-11","conditions":"Infections, Streptococcal","enrollment":450},{"nctId":"NCT00197002","phase":"PHASE3","title":"Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-11","conditions":"Hepatitis A","enrollment":521},{"nctId":"NCT00146835","phase":"","title":"Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Hepatitis B, Poliomyelitis, Diphtheria","enrollment":120794},{"nctId":"NCT00464945","phase":"PHASE3","title":"Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-06","conditions":"Pneumococcal Vaccines","enrollment":269},{"nctId":"NCT00164411","phase":"PHASE1","title":"Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-01","conditions":"Pneumococcal Infections","enrollment":30},{"nctId":"NCT00824850","phase":"PHASE2","title":"Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Pneumococcal Conjugate Vaccine","enrollment":75},{"nctId":"NCT01346007","phase":"PHASE4","title":"Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2009-01","conditions":"Idiopathic Nephrotic Syndrome","enrollment":50},{"nctId":"NCT00885625","phase":"PHASE4","title":"7-valent Pneumococcal Conjugated Vaccination","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2009-03","conditions":"Invasive Pneumococcal Disease","enrollment":350},{"nctId":"NCT01075438","phase":"","title":"Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2010-03","conditions":"Ataxia Telangiectasia","enrollment":20},{"nctId":"NCT00999739","phase":"PHASE3","title":"Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults","status":"UNKNOWN","sponsor":"Hospital Universitari Son Dureta","startDate":"2007-12","conditions":"Pneumococcal Vaccines, HIV, HIV Infections","enrollment":220},{"nctId":"NCT00143780","phase":"PHASE4","title":"Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2002-05","conditions":"Bone Marrow Transplant","enrollment":70},{"nctId":"NCT00152802","phase":"PHASE4","title":"Pneumonia Vaccine in Liver Transplant Recipients: a Booster Strategy Using a Conjugate Vaccine","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2005-01","conditions":"Transplant","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pneumococcal conjugate vaccine"],"phase":"phase_3","status":"active","brandName":"Prevenar (Wyeth)","genericName":"Prevenar (Wyeth)","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}